Glutathione S-transferase GSTP1 genotypes are associated with response to androgen ablation therapy in advanced prostate cancer

Abstract We determined whether the glutathione S -transferase GSTP1 Ile 105 →Val 105 substitution is associated with response to androgen ablation therapy in patients with advanced prostate cancer. As response may be associated with tumor grade, Gleason score, clinical T stage and presence of metastases we also determined if GSTP1 genotypes were associated with these prognostic parameters. We speculated that GSTP1 Ile 105 /Ile 105 would be linked with good response to androgen ablation therapy and, low/moderate tumor grade, 1/2 clinical T-stage, Gleason score P =0.70) indicating that allelism in GSTP1 is not associated with susceptibility. There was no association between GSTP1 (Ile 105 /Ile 105 versus Ile 105 /Val 105 and Val 105 /Val 105 ) and grade ( P =0.28, OR=0.92), Gleason score ( P =0.84, OR=0.94) or metastatic state ( P =0.68, OR=0.88) though the frequency of GSTP1 Ile 105 /Ile 105 was higher in cases with stage 1/2 tumors than those with stage 3/4 tumors ( P =0.03, OR=1.89). GSTP1 Val 105 /Val 105 was also associated with response to hormone ablation therapy. Thus, the GSTP1 Ile 105 /Ile 105 frequency was significantly higher in 86/118 patients who demonstrated a good response than in those with poor response ( P =0.03, OR=2.70). We speculate that the association of GSTP1 with response results from an effect of the gene product early in carcinogenesis.